STOCK TITAN
  1. Home
  2. News
  3. MRVI

Maravai LifeSciences Holdings Inc - MRVI STOCK NEWS

Welcome to our dedicated news page for Maravai LifeSciences Holdings (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai LifeSciences Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Maravai LifeSciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Maravai LifeSciences Holdings's position in the market.

News
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
Rhea-AI Summary
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), announces the opening of a new cGMP mRNA manufacturing facility in San Diego. The facility is designed to support late-phase drug developers and meet the increasing demand for mRNA-based medicine. With state-of-the-art equipment and increased manufacturing capacity, the facility aims to advance the field of mRNA therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
Rhea-AI Summary
Maravai LifeSciences, Inc. (MRVI) will announce its first quarter 2024 financial results on May 8, 2024. The company is a global provider of life science reagents and services. Investors can join the conference call or webcast to learn more about the operating results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences earnings
-
News
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
Rhea-AI Summary
Maravai LifeSciences, Inc. (MRVI) will participate in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum on March 19, 2024. Trey Martin, CEO, will engage in a fireside chat at 11:15 a.m. PDT. The event will be virtually broadcasted on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
News
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Maravai LifeSciences Holdings, Inc. reported financial results for Q4 and full year 2023, with quarterly revenue of $74.1 million, net loss of $(110.0) million, and annual revenue of $288.9 million. The company introduced a revenue guidance range of $265.0 million to $285.0 million for 2024. Maravai highlighted product innovation, partnerships, and awards, including patents for CleanCap technology and strategic partnerships. The CEO emphasized the focus on expanding the product portfolio, market leadership in the mRNA space, and introducing innovations to meet customer needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
63.6%
Tags
earnings
-
News
TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
Rhea-AI Summary
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), secures global patents for its CleanCap® Capping Technology, enhancing the production of synthetic mRNA for innovative medicines. The patents from China and Canada strengthen TriLink's intellectual property protection, complementing existing patents in major markets. CleanCap® technology has been pivotal in developing COVID-19 vaccines and promises faster drug commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
News
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
Rhea-AI Summary
Maravai LifeSciences, Inc. (MRVI) will announce its Q4 and full year 2023 financial and operating results on February 22, 2024. The company is a global provider of life science reagents and services to researchers and biotech innovators. A conference call and webcast will be hosted on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences earnings
News
Maravai LifeSciences Announces November 2023 Investor Conference Schedule
Rhea-AI Summary
Maravai LifeSciences, Inc. (NASDAQ: MRVI) to participate in investor conferences in November 2023. CEO and CFO to join fireside chats at Stifel Healthcare Conference and Jefferies London Healthcare Conference. Webcasts available on Maravai's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Maravai LifeSciences Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Maravai LifeSciences Holdings, Inc. (MRVI) Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic with $66.9 million Quarterly Revenue and a 15% Workforce Reduction
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.69%
Tags
earnings
-
News
TriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’
Rhea-AI Summary
TriLink BioTechnologies, a Maravai LifeSciences company, has launched its Analytical Sciences Center of Excellence (ASCE) hub in San Diego. The 4,000-square-foot lab will serve as the centralized hub for advanced testing of nucleic acids, minimizing delays and costs associated with outsourced testing. The center of excellence will expand analytical capabilities, develop new methodologies, and improve NMR, NGS, and LNP characterization. TriLink is a leader in mRNA specific analytical services and has developed 10 unique methods for mRNA characterization. The ASCE will support developers in advancing their drugs, starting with plasmid DNA and continuing through mRNA manufacturing and release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
News
Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
Rhea-AI Summary
Maravai LifeSciences to announce Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences earnings
Stock MRVI logo
Maravai LifeSciences Holdings Inc

Nasdaq:MRVI

MRVI Rankings

#2427 Ranked by Market Cap
#4968 Ranked by Stock Gains
N/A Ranked by Dividends

MRVI Stock Data

2.11B
98.47M
2.37%
102.51%
3.87%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MRVI

maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri